Key Takeaways:
(Bloomberg) -- The Schall Law Firm announced an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of securities laws, a move that follows a steep decline in the company’s stock price after a regulatory setback.
"The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors," The Schall Law Firm said in a statement released May 17.
The inquiry stems from Replimune's announcement on April 10, 2026, that it had received a complete response letter from the U.S. Food and Drug Administration. The letter pertained to the company's Biologics License Application for RP1, a treatment for advanced melanoma. According to Replimune, the FDA cited a disagreement over the suitability of the submitted data.
Following the disclosure, shares of Replimune fell by 64.3% on April 13, 2026, wiping out significant shareholder value. The law firm is now soliciting shareholders who suffered a loss to participate in its investigation.
The investigation by a prominent shareholder rights litigation firm introduces a new layer of risk for Replimune, which is already dealing with the clinical and regulatory challenges for its lead drug candidate. Investors will be closely watching for the company's next steps in addressing the FDA's concerns and any potential legal proceedings.
This article is for informational purposes only and does not constitute investment advice.
